Prot #BLU-285-1303: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

  • Agulnik, Mark (PD/PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date9/20/189/20/21

Funding

  • Syneos Health, Inc. (Prot #BLU-285-1303)
  • Blueprint Medicines Corporation (Prot #BLU-285-1303)